XP Power Limited (LSE:XPP) shares fell 0.59% to 1,688.0p in the latest session, placing the power conversion specialist among the notable decliners on the London market. The move follows interim results that showed sharply higher orders and profit, a lower net debt position and a continued suspension of dividends.
The company supplies power control components used in semiconductor equipment, industrial technology and healthcare. Investors are focused on whether the sharp rise in order intake turns into second-half revenue and further deleveraging.
Key Highlights
For the six months to 30 June 2026, XP Power reported revenue of £109.1 million, down 2% as reported and up 2% at constant currency.
Order intake was £167.2 million, up 48% as reported and 55% at constant currency, giving a book-to-bill ratio of 1.53x, compared with 1.02x in H1 2025. The order book rose to £173.9 million from £121.8 million.
Adjusted operating profit increased to £8.6 million from £4.8 million, and the adjusted operating margin was 7.9%, compared with 4.3%. Adjusted gross margin rose 450 basis points to 45.9%.
Net debt fell 18% to £47.7 million, with leverage of 1.3x, expected to reduce to around 1.0x by the year-end.
About XP Power Limited
XP Power Limited (LSE:XPP) designs and manufactures power converters and related products that convert and control electricity for electronic equipment. Its customers are mainly equipment manufacturers in demanding sectors where reliability matters.
The group reports across three main markets: semiconductor manufacturing equipment, industrial technology and healthcare. In H1 2026, semiconductor revenue was £44.1 million, industrial technology £44.6 million and healthcare £20.4 million.
XP Power sells through direct sales to large customers and distribution channels, and its results are affected by customer inventory cycles, tariffs and currency movements.
Why Is LSE:XPP Down Today?
The 0.59% decline to 1,688.0p reflects a balance between encouraging order data and a modest reported revenue position. Revenue in the half was lower as reported, and the company's results are weighted towards the second half.
Tariff changes affected reported revenue. After a US Supreme Court ruling in February 2026 that invalidated certain tariffs, a replacement global tariff of 10% followed. Lower tariff recovery reduced H1 revenue and is expected to have a larger effect in H2, although the company said it has no impact on profit.
No interim dividend was declared. Payments have been suspended since late 2023, and debt reduction remains the priority until leverage approaches the 0x to 1x target range.
Key Reasons Behind the Downtick
The first factor is second-half dependence. Management expects revenue growth in H2, supported by £135 million of firm orders scheduled for delivery, so delivery against that book is important.
The second factor is healthcare weakness. Healthcare revenue fell 13% to £20.4 million, although orders were £27.8 million with a book-to-bill of 1.36x and management expects a recovery in H2.
Third, dividends remain suspended. This limits income returns while the company reduces debt.
Another consideration is leverage. At 1.3x, leverage is lower than before but still above the top of the target range.
Finally, statutory earnings remain much lower than adjusted earnings, with statutory diluted EPS of 3.6p compared with adjusted diluted EPS of 14.2p.
Key Growth Catalysts
The most important catalyst is the semiconductor equipment market. Orders were £79.9 million, up 116%, with a record book-to-bill of 1.81x, suggesting customers are placing larger orders.
Industrial technology is another driver. Revenue grew 9% to £44.6 million, with orders of £59.5 million and a book-to-bill of 1.33x, helped by distribution demand in the US.
Margin improvement is a third catalyst. The adjusted operating margin rose to 7.9% from 4.3% and adjusted EPS increased to 14.2p from 0.4p.
Deleveraging is another factor. Net debt fell to £47.7 million, and management expects leverage of around 1.0x by year-end, which could eventually create room to resume dividends.
Finally, the company maintained full-year expectations and said it remains confident in its long-term targets.
Risks
The most significant risk for LSE:XPP is a slowdown in semiconductor equipment spending, which is cyclical and can change quickly.
Tariff and trade policy changes can affect pricing, recoveries and supply chains.
Execution risk is relevant too. Converting a £173.9 million order book into H2 revenue depends on manufacturing, component supply and customer scheduling.
Currency movements matter since the group reports in sterling but sells globally; revenue was down 2% reported and up 2% at constant currency.
Finally, leverage and the lack of dividends mean cash generation remains a priority.
Valuation
The valuation of LSE:XPP is likely to be viewed through order momentum, margin recovery and debt reduction.
At 1,688.0p, investors are weighing a business with a book-to-bill ratio of 1.53x, improving margins and falling net debt against a cyclical end market, suspended dividends and revenue weighted to the second half.
Reference points include adjusted operating profit of £8.6 million, adjusted EPS of 14.2p and net debt of £47.7 million.
The central valuation debate is whether orders can convert into sustained profit growth while leverage falls toward target.
What Investors Should Watch Next
The next key event is the company's full-year results and trading update, which should show whether H2 revenue growth and margin expectations were met.
Investors should follow semiconductor order trends, healthcare recovery, tariff effects, leverage and any decision on resuming dividends.
For LSE:XPP, the central question over the coming quarters is whether the record order book can deliver higher revenue and cash generation.






Please wait processing your request...